NCT00427219 is a Phase 2 clinical trial of Ozarelix in Benign Prostatic Hypertrophy, sponsored by Spectrum Pharmaceuticals, Inc.

Who is sponsoring NCT00427219?

NCT00427219 is sponsored by Spectrum Pharmaceuticals, Inc.

What drugs are being tested in NCT00427219?

Interventions in NCT00427219: Ozarelix, Placebo.

What condition does NCT00427219 study?

NCT00427219 studies Benign Prostatic Hypertrophy.

Is NCT00427219 still recruiting?

NCT00427219 is currently completed. Last updated 15 October 2021.

Last reviewed 2021-10-15 · How we verify

NCT00427219

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

Completed Phase 2 Last updated 15 October 2021

What this trial tests

Phase 2 trial testing Ozarelix in Benign Prostatic Hypertrophy in 74 participants. Completed in 27 February 2008.

Timeline

23 January 2007

Primary endpoint
27 February 2008

27 February 2008

Quick facts

Lead sponsor	Spectrum Pharmaceuticals, Inc
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	74
Start date	23 January 2007
Primary completion	27 February 2008
Estimated completion	27 February 2008
Sites	13 locations across United States

Drugs / interventions tested

Ozarelix — full drug profile →
Placebo

Conditions studied

Benign Prostatic Hypertrophy — all drugs for Benign Prostatic Hypertrophy →

Sponsor

Spectrum Pharmaceuticals, Inc — full company profile →

Who can join

50 and older, male only, with Benign Prostatic Hypertrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Spectrum Pharmaceuticals, Inc trials

Trials by the same sponsor.

NCT05378763 — A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 2 · Phase 3 · suspended
NCT04981704 — A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacok · Phase 1 · completed
NCT04402008 — Study of Poziotinib in Japanese Patients With NSCLC · Phase 1, PHASE2 · terminated
NCT04436562 — Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects · Phase 1 · completed
NCT04187898 — Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00427219 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spectrum Pharmaceuticals, Inc
Last refreshed: 15 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00427219.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing